InflaRx (IFRX)
Develops C5a-pathway medicines centered on oral izicopan for inflammatory and renal diseases.
$2.52
Pre-market+0.22 (+9.66%)
At close$2.30(+6.25%)
Something off on this page? Send us feedback.
Next report
Nov 9, 2026
estimated · in 67 days
EPS estimate
−$0.07
Revenue estimate
$6.1K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.09−$0.14−$0.24−$0.16−$0.17−$0.09−$0.11Pending
Estimate−$0.27−$0.18−$0.24−$0.16−$0.18−$0.17−$0.07−$0.07
Surprise+66.7%+22.2%0.0%0.0%+5.6%+47.1%−65.1%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$438—$46.4K$27.9K−$17.6K——Pending
Estimate$47.0K$19.4K$26.0K$26.2K$27.3K$9.0K$6.0K$6.1K
Surprise−100.9%—+78.6%+6.6%−164.5%———
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.07 | — | — |
| Aug 2026 | −$0.07 | −$0.11 | −65.1% |
| May 2026 | −$0.17 | −$0.09 | +47.1% |
| Mar 2026 | −$0.18 | −$0.17 | +5.6% |
| Nov 2025 | −$0.16 | −$0.16 | 0.0% |
The latest year is open to everyone — the 38 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Oct 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Apr 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Nov 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.07 | — | — | $6.1K | — | — | — |
| Aug 6, 2026 | −$0.07 | −$0.11 | −65.1% | $6.0K | — | — | −2.8% |
| May 7, 2026 | −$0.17 | −$0.09 | +47.1% | $9.0K | — | — | −2.6% |
| Mar 19, 2026 | −$0.18 | −$0.17 | +5.6% | $27.3K | −$17.6K | −164.5% | +3.3% |
| Nov 10, 2025 | −$0.16 | −$0.16 | 0.0% | $26.2K | $27.9K | +6.6% | +4.4% |
The latest year is open to everyone — the 38 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 7, 2025 | |||||||
| Mar 20, 2025 | |||||||
| Nov 8, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 8, 2024 | |||||||
| Mar 21, 2024 | |||||||
| Nov 1, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 11, 2023 | |||||||
| Mar 22, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 5, 2022 | |||||||
| May 12, 2022 | |||||||
| Mar 24, 2022 | |||||||
| Nov 5, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 12, 2021 | |||||||
| Mar 25, 2021 | |||||||
| Oct 29, 2020 | |||||||
| Jul 30, 2020 | |||||||
| May 21, 2020 | |||||||
| Apr 29, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 23, 2019 | |||||||
| Mar 28, 2019 | |||||||
| Nov 21, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 17, 2018 | |||||||
| Mar 29, 2018 | |||||||
| Dec 21, 2017 | |||||||
| Nov 8, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||